Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult-to-treat malignancies with a dismal 5-year survival rate of only 5--7% ([@B42]). Despite some progress over the last decade, systemic chemotherapy for disseminated PDAC has overall limited efficacy and significant toxicity, while PDACs have been notoriously resistant to molecularly targeted agents and immunotherapy. At the same time, PDAC is projected to become the second leading cause of cancer related deaths in the United States and Europe by 2030 ([@B39]), underscoring the pressing need to develop more successful strategies tackling pancreatic cancer ([@B32]; [@B42]).

Given the bleak prospects of clinically manifest PDAC, early detection at the pre-metastatic stage remains a major goal of translational research efforts ([@B7]). PDACs develop from precursor lesions including pancreatic intraepithelial neoplasia (PanIN) ([@B19]; [@B46]), intraductal papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms (MCNs) ([@B23]). Detecting precursor lesions is still challenging but would improve the chance for curative treatment drastically ([@B11]) and highlights the need of biomarkers for PDAC. Given the rare detection of non-invasive pancreatic precursor lesions, the amount of such data is very limited and complicates the biomarker discovery. Studying late stage PDAC samples, however, might also give insights at the onset of the disease and therefore make them useful in biomarker research.

To date, carbohydrate antigen 19-9 (CA19-9) is the clinically best established blood-based biomarker for PDAC ([@B15]; [@B17]). However, the marker's low sensitivity and specificity disallows its application for early detection. Molecular imaging techniques are being developed for detection of PDAC, but their applicability will probably remain limited to high-risk-situations and radiographic signs are similar to the ones of pancreatitis ([@B34]).

In the search for PDAC biomarkers, multiple studies have analyzed the transcriptome and proteome of pancreatic cancer patient tissues ([@B16]; [@B4]), urine ([@B38]), and most recently blood samples ([@B6]). Particularly, the transcriptome displays major differences between PDAC and pancreatic non-tumor tissues, which is an ideal prerequisite to construct a robust PDAC biomarker. PDAC has previously been found to display different tumor subtypes in the transcriptome ([@B8]; [@B33]; [@B3]). Most recently, Bailey et al. identified four tumor subtypes denominated squamous, ADEX (abnormally differentiated endocrine exocrine), pancreatic progenitor and immunogenic. This underlines the importance of transcriptomics to capture the wide range of responses and corroborates the complexity and variability of the disease as well as the difficulty in developing a comprehensive PDAC biomarker. Transcriptional sensitivity to tumor-normal differences is due to thousands of differentially regulated genes per data set ([@B2]; [@B47]; [@B20]), however, the small overlap of genes between studies impedes the choice of promising targets and their experimental validation in clinical trials ([@B21]). This cohort variability is probably due to varying study designs, different responses of tumor subtypes and/or the transcriptional heterogeneity of PDAC between patients. Therefore, a multi-gene signature resulting from many different studies is required -- large enough to capture the multiple facets of the disease and small enough to be applied on individual patient material. Through meta-analysis of multiple data sets a consent of as many as 827 genes have been found to be significantly up-regulated in PDAC ([@B16]) and as low as five have been previously used for prediction analysis ([@B4]), suggesting meta-analysis as promising tool to identify a gene signature that fulfills the demanded needs.

Here, we present a novel meta-analysis-based approach to identify a robust tissue-based gene signature for classification of PDAC through the incorporation of several independent transcriptome studies. Identified genes were clustered based on gene co-expression and annotated with tissue compartment. A survival analysis of the gene clusters in data from The Cancer Genome Atlas (TCGA) revealed their prognostic behavior for PDAC and allowed the reduction to a clinically feasible signature of 17 genes. These genes were then validated in independent cohorts to assess the applicability of the biomarker not only to pancreatic cancer tissues but also its capability to identify pancreatic precursor lesions and discriminate pancreatitis in fresh-frozen (FF) as well as formalin-fixed paraffin embedded tissues (FFPE). Finally, validation in patient-derived material on transcript and protein level, using qPCR and ELISA-based protein detection in blood plasma indicated the translational potential of the described biomarker panel.

Results
=======

Multiple Genes Are Required to Classify PDAC in Independent Data Sets
---------------------------------------------------------------------

We collected 18 fresh-frozen PDAC (tumor content 15--80%) and 13 pancreatic non-tumor (normal pancreatic tissue distant to tumor side) tissues and analyzed their transcriptomes using Illumina humanRef-12 bead arrays. After preprocessing and filtering, 21168 genes were further analyzed. Gene set enrichment analysis ([@B30]) using ConsensusPathDB ([@B26]) identified multiple pathways altered in PDAC samples associated with the development and progression of epithelial malignancies including pancreatic, breast, and lung cancer, confirming the expected pathways of a PDAC cohort and making it suitable for down-stream analysis. Up-regulated pathways included for example the transforming growth factor beta receptor (TGFβR), tumor necrosis factor alpha (TNFα), T-cell antigen receptor (TCR), mitogen-activated protein kinase (MAPK), wingless-related integration site (Wnt) and integrin signaling. In addition, pathways involved in pancreatic secretion were significantly down-regulated (Supplementary Figure [S1](#SM5){ref-type="supplementary-material"} and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}).

A schematic flow chart of the performed analysis for biomarker identification is presented in **Figure [1](#F1){ref-type="fig"}**. First, we sought to identify a minimum predictive gene signature to classify PDAC from non-tumor tissues. Prediction performance was evaluated by 10-fold cross-validation (CV) using a support vector machine (SVM) and features were selected according to log2-fold change (log~2~FC) differences in an inner CV on the training samples to reduce bias through overfitting and to assure independence in the testing set (see Single Set biomarker Identification for M1in Materials and Methods).

![Schematic workflow of analyses.](fgene-09-00108-g001){#F1}

We found two genes, syncoilin (SYNC) and chymotrypsinogen B2 (CTRB2), to discriminate between tumor and non-tumor tissue in data set M1 (**Figure [2A](#F2){ref-type="fig"}**, blue line). To validate these genes on independent data sets, we selected five publicly available cohorts ([@B2]; [@B36]; [@B12]; [@B47]; [@B20]) with microarray gene expression data that included a minimum of five samples of both human PDAC and pancreatic non-tumor fresh-frozen tissues (M2--M6, shown in **Table [1](#T1){ref-type="table"}**). Cross-validation classification performances with these two genes on M2-M5 (SYNC and CTRB2 were missing in data set M6) revealed poor and highly varying AUCs between 0.50 and 0.84 (**Figure [2A](#F2){ref-type="fig"}**), clearly indicating overfitting toward our data set, that might arise from sample collection, data preparation, and/or microarray analysis. Therefore, derivation of a small number of classifier genes from a single data set are context-dependent and a more robust gene signature based on multiple data sets is required.

![ROC curves to visualize classification performance between PDAC and non-tumor samples. **(A)** Classification performance with two genes (SYNC and CTRB2) selected in inner cross validation of data set M1 (blue line) and validation of these genes in independent data sets M2--M5. **(B)** Classification performances for testing data sets M1--M6 from the meta-analysis. 95% confidence interval of AUC is presented in brackets.](fgene-09-00108-g002){#F2}

###### 

Summary of data sets used in this study for meta- and validation analysis, including data identifiers, tumor and non-tumor samples and tissue type \[fresh-frozen (FF) or formalin fixed paraffin-embedded (FFPE)\], feature size after pre-processing, microarray chip, original reference and public repository.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          ID   Pancreatic tumor samples                                          Pancreatic non-tumor samples                                                        Size    Platform                      Reference   Source
  --------------------------------------- ---- ----------------------------------------------------------------- ----------------------------------------------------------------------------------- ------- ----------------------------- ----------- ---------------------
  Meta-analysis                           M1   18 FF PDAC tissues                                                13 FF tissues                                                                       21168   Illumina                      --          In house: GSE101448

                                          M2   36 FF PDAC tissues                                                36 FF paired tissues                                                                20156   Affymetrix U133plus2.0        [@B2]       GSE15471

                                          M3   45 FF PDAC tissues                                                45 FF paired tissues                                                                18232   Affymetrix HumanGene1.0ST     [@B47]      GSE28735

                                          M4   25 FF PDAC tissues                                                7 FF tissues                                                                        20156   Affymetrix U133plus2.0        [@B12]      GSE32676

                                          M5   36 FF tumor tissues                                               16 FF tissues                                                                       20155   Affymetrix U133plus2.0        [@B36]      GSE16515

                                          M6   28 FF PDAC tissues                                                7 FF tissues                                                                        13625   Affymetrix HumanExon1.0STv2   [@B20]      GSE56560

  Validation-analysis PDAC                V1   6 FFPE PDAC tissues                                               6 FFPE tissues                                                                      21168   Illumina                      --          In house: GSE101448

                                          V2   3 FF PDAC and 3 FFPE PDAC tissues                                 3 FF tissues, 1 FFPE tissue and 10 FFPE pancreatitis tissues                        21163   Illumina                      --          In house: GSE101462

                                          V3   Microdissected: 14 FF PDAC                                        11 FF tissues                                                                       17936   Affymetrix U133a and U133b    [@B18]      E-MEXP -950

                                               Microdissected: 6 FF PDAC and 11 FF adjacent stroma tissues       6 FF tissues and 9 FF pancreatitis tissues                                          17936   Affymetrix U133a and U133b    [@B37]      E-MEXP -1121

                                          V4   178 FF pancreatic cancer tissues                                  405 bladder, 1080 breast, 280 colon, 369 liver, and 496 thyroid cancer FF tissues   19722   RNA-seq IlluminaHiSeq2000     --          TCGA

  Validation-analysis precursor lesions   V5   4 FF PDAC and 13 FF PanIN-2/3 lesions tissues                     3 FF pancreatic healthy donor tissues                                               17936   Affymetrix U133a and U133b    [@B9]       GSE43288

                                          V6   3 IPMNs, 6 IPMAs and 6 IPMCs FF tissues                           7 normal pancreatic duct FF tissues                                                 20546   Affymetrix U133plus2.0        [@B22]      GSE19650

                                          V7   3 PDAC and 3 PanIN FF tissues from Pdx1-cre; KrasLSL^G12D^ mice   3 FF tissues from Pdx1-cre; KrasLSL^G12D^ mice                                      20917   Affymetrix mogene10sttran\    [@B27]      GSE33322
                                                                                                                                                                                                             scriptcluster                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To derive a cross-study biomarker, we first rendered data sets M1--M6 comparable through application of a meta-analysis algorithm (**Figure [3](#F3){ref-type="fig"}**). Meta-analysis avoids batch effects arising from different study designs and/or microarray platforms by performing analyses within each data set and not comparing samples across different studies. Briefly, data sets (M1--M6) were split in a leave-one-out-cross-validation (LOOCV) into testing (hold out data set) and training sets, with the latter being used for feature selection. Within the feature selection, the algorithm ranked the genes according to their absolute log~2~FC within each training set, aggregated the rankings and optimized the number of genes *n* that were selected from the combined ranking in an inner LOOCV (see Meta-Analysis Biomarker Identification for M1--M6 in Materials and Methods). The classification results for data sets M1--M6, being held out as testing sets, revealed performances with AUCs between 0.91 and 1.0 and resulted in an average prediction performance of AUC~average~ = 0.97 (**Figure [2B](#F2){ref-type="fig"}**). The optimal number of classifier genes per data set ranged between 35 and 50, depending on which data sets were used for feature selection. The union of all classifier genes comprised a total of 81 unique genes (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). Additionally, we tested other feature rankings, such as *p*-value or SVM weights, but both resulted in larger final gene lists (96 and 134) at equal or worse prediction performance (Supplementary Figures [S2A,B](#SM6){ref-type="supplementary-material"}). A control run with rearranged class labels led to random prediction performances with an AUC = 0.5 within a 95% confidence interval, which indicated the absence of any bias by the meta-analysis (Supplementary Figure [S2C](#SM6){ref-type="supplementary-material"}). Taken together, the average prediction performance improved by ΔAUC = 0.21 compared to a single-study analysis (AUC~average~ = 0.76) emphasizing the robustness of the selected classifier genes and the need of considering multiple data sets in biomarker identification.

![Meta-analysis workflow of N gene expression data sets with two conditions (gray and black). One data set is held out for testing (e.g., M1), while the others (e.g., M2--M6) are used for feature selection. First, for each training data set gene rankings are calculated and subsequently combined. Secondly, the number of selected genes *n ∈* {5,10, ..., 50} is optimized by evaluating their overall prediction performance in an inner LOOCV of the training data sets. Then *n* with the best prediction performance is chosen and the top *n* genes are selected from the combined ranking. Finally, the prediction performance for the selected genes of the testing data set is evaluated in a CV with SVM classification (see **Figure [2B](#F2){ref-type="fig"}**). This is repeated until every data set (M1--M6) was left out for testing once. The selected genes in each round combine to a total of 81 unique classifier genes (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). A detailed description of the meta-analysis can be found in the "Meta-Analysis Biomarker Identification for M1--M6" in Materials and Methods.](fgene-09-00108-g003){#F3}

Classifier Genes Originate From Distinct Tissue Compartments and Tumor-Specific Subtypes
----------------------------------------------------------------------------------------

Consensus clustering of the expression values of the 81 classifier genes across the data sets M1--M6 resulted in four distinct clusters (**Figure [4A](#F4){ref-type="fig"}**). We then functionally annotated the classifier genes according to the gene labels from [@B33], where available (76 out of 81; Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). In this study, the authors used non-negative matrix factorization on cancerous and normal pancreatic samples to assign 19749 genes to one of 14 distinct gene labels according to function or tissue origin. Gene labels included normal compartments (distant organs, normal pancreas) and tumor compartments (stroma, tumor subtypes). Interestingly, six gene labels from [@B33] overlapped significantly with the four clusters identified from consensus clustering (χ^2^ test; *p* \< 2e-16; **Figure [4A](#F4){ref-type="fig"}**).

![**(A)** Heatmap of consensus matrix from consensus clustering of 81 classifier genes. Cluster membership, gene set labels according to [@B33] as well as the average log2FC between tumor and normal tissues (M1--M6) are depicted in the annotation bars on the top. **(B)** Kaplan--Meier plots for TCGA data with patient grouping based on low, intermediate and high gene expression of genes in clusters 1--4 (Supplementary Figure [S3](#SM7){ref-type="supplementary-material"}).](fgene-09-00108-g004){#F4}

In detail, 27 of 35 genes in cluster 1 were labeled as exocrine pancreas, including, e.g., pancreatic lipase-related proteins (PNLIPRP) 1 and 2 and serpine family 1 member 2 (SERPINI2). Two genes were labeled as endocrine pancreas: islet amyloid polipeptide (IAPP) and aryl-hydrocarbon receptor repressor (KIAA1234), one gene, carboxypeptidase B1 (CBP1), was assigned to liver, and four genes had no annotation (**Figure [4A](#F4){ref-type="fig"}**). Furthermore, all genes related to cluster 1 were down-regulated in PDAC compared to non-tumor tissue.

In contrast, all genes in clusters 2--4 were up-regulated in tumor versus non-tumor tissue (log2FC \> 0). Genes (*n* = 10) in cluster 2 were entirely labeled as activated stroma (**Figure [4A](#F4){ref-type="fig"}**), containing periostin (POSTN), fibronectin 1 (FN1) and collagens (COL10A1, COL11A1), which have already been identified as deregulated in precursor lesions of pancreatic cancer ([@B14]).

Hierarchical clustering indicated the closest similarity in expression of genes in clusters 3 and 4, probably because cluster members were mainly identified as classical and basal-like tumor genes (**Figure [4A](#F4){ref-type="fig"}**). 11 out of 12 genes in cluster 3 and 10 out of 26 genes in cluster 4 were labeled as classical tumor genes with the remaining being primarily basal-like genes. The latter include, e.g., laminins and keratins, whereas the former contains adhesion-associated and epithelial genes.

Taken together, consensus clustering and functional annotation of the classifier genes suggest the presence of different biological processes in PDAC progression and their importance for PDAC prediction.

Classifier Genes Correlate With Patient Survival
------------------------------------------------

Despite an overall poor prognosis, the clinical course of PDAC patients shows remarkable heterogeneity. To examine how gene expression from the four consensus clusters correlates with patient survival, we analyzed survival and gene expression data of 178 pancreatic cancer patients from the cancer genome atlas (TCGA). Hierarchical clustering divided patients into low, intermediate, and high gene expression groups for the individual consensus gene clusters of our biomarker (Supplementary Figure [S3](#SM7){ref-type="supplementary-material"}).

Indeed, genes in clusters 2--4 were highly associated with survival. Low gene expression groups displayed a 5-year survival rate of 79, 92, and 100%, respectively (**Figure [4B](#F4){ref-type="fig"}**), while intermediate and high gene expression groups showed significantly worse survival (log-ranks *p* = \[0.00014, 0.000034, 0.0000026\] in clusters 2--4). Thus, genes in clusters 2--4 have a prognostic significance for pancreatic cancer patients. Contrary to this, there was no survival association among the expression groups in cluster 1 (log-rank *p* = 0.85, **Figure [4B](#F4){ref-type="fig"}**).

For better clinical applicability, we then sought to reduce the number of genes in the classifier by making use of both the cluster and survival information. Thus, we considered only those genes impacting survival (clusters 2--4) and those that were selected in every hold out data set of the meta-analysis (**Figure [3](#F3){ref-type="fig"}**), i.e., the most robust genes across the cohorts M1--M6. In total, 17 prognostic classifier genes, selected from the 81 classifier genes, remained for PDAC detection and validation experiments (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}, marked in yellow).

Diagnostic Potential of the 17-Gene Classifier in PDAC
------------------------------------------------------

Next, we tested the diagnostic potential of the reduced 17-gene classifier for the following four aspects. For clinical application, it is important for (i) the classifier genes to be detectable in formalin-fixed paraffin-embedded (FFPE) samples. Additionally, clinical signs and radiographic findings of PDAC and pancreatitis are often indistinguishable, highlighting the need of a (ii) PDAC biomarker to be insensitive to pancreatitis ([@B34]). Another scope of application is (iii) the specificity to PDAC compared to other cancers and last but not least it is beneficial for the classifier genes to be (iv) detectable in pancreatic precursor lesions, which would allow diagnosis at a potentially treatable stage.

To this end, we analyzed the putative clinical prediction performance of the reduced set of classifier genes on seven independent validation transcriptome data sets (V1--V7, **Table [1](#T1){ref-type="table"}**). These sets contain gene expression data of fresh-frozen (FF) and FFPE PDAC as well as non-tumor tissues (V1, V2), microdissected PDAC together with its comprised tumor-adjacent stroma (V3), pancreatitis (V2, V3), other cancer entities (V4), and lastly pancreatic precursor lesions of human and mouse (V5--V7).

Prediction of the FFPE sample validation cohort resulted in an optimal separation of PDAC and non-tumor tissues (AUC = 1.00; **Figure [5A](#F5){ref-type="fig"}**, V1). Data set V2 was comprised of a mix between FF and FFPE samples, including PDAC, non-tumor, and pancreatitis tissues. The 17-gene classifier separated tumor from non-tumor tissues and pancreatitis with an AUC of 0.98, thus confirming its specificity to PDAC and insensitivity to pancreatitis (**Figure [5A](#F5){ref-type="fig"}**, V2).

![ROC curves of prediction performances of the 17-gene classifier in seven independent data sets (see **Table [1](#T1){ref-type="table"}**) for **(A)** validation in PDAC and **(B)** validation in pancreatic precursor lesions. Values in brackets indicate the 95% confidence interval of the AUCs. **(C,D)** qPCR validation of the 17-gene classifier in 8 pancreatic tumors and one liver metastasis. Log2-fold differences between tumor samples and healthy donors are shown sorted by individual genes **(C)** or tumor patients **(D)**.](fgene-09-00108-g005){#F5}

Next, we applied the 17-gene classifier on V3, which consists of microdissected epithelial PDAC cells, tumor-adjacent stroma, non-tumor tissue, and pancreatitis, all obtained from FF tissues ([@B18]; [@B37]). Discriminating tumor (PDAC and adjacent stroma) from non-tumor (normal and pancreatitis) resulted in an AUC of 0.83 (**Figure [5A](#F5){ref-type="fig"}**, V3).

The tumor-type specificity of the classifier genes was examined by testing the discriminating capability of 178 FF pancreatic cancer tissues compared to \>2500 non-pancreatic FF cancer samples (bladder, breast, colon, liver, thyroid) from TCGA. Applying a cross-validation (CV) approach with SVM classification resulted in an AUC of 0.99 (**Figure [5A](#F5){ref-type="fig"}**, V4), which confirmed the specificity of the classifier genes to pancreatic cancer.

Lastly, we determined the diagnostic potential in early disease stages (**Figure [5B](#F5){ref-type="fig"}**), whereby we could find only one publicly available study (data set V5). The latter contained FF tissues of three healthy donors, 13 dysplastic PanIN-2 and focal PanIN-3 lesions and four PDAC samples ([@B9]). Using CV with SVM classification for our classifier genes, we perfectly discriminated PDAC and PanINs from healthy donors (**Figure [5B](#F5){ref-type="fig"}**, V5). Because IPMNs are the second major origin of PDAC after PanIN ([@B22]), we applied the 17-gene classifier to distinguish 15 IPMNs from 7 normal pancreatic duct FF tissues. Again, we used CV with SVM classification and obtained a classification performance of AUC = 0.96 (**Figure [5B](#F5){ref-type="fig"}**, V6). Because of the vicious cycle of no symptoms at the beginning of the disease and the resulting late diagnosis, early disease stages of human PDAC are very rare. Therefore, we tested the 17-genes in a mouse model to monitor PDAC progression ([@B27]) for further validation of the detectability of PanIN samples. First, human identifiers were matched to mouse and then normal FF tissues were classified against PanIN and PDAC FF tissues based on the 16 successfully matched genes (excluding S100P), which resulted in optimal separation (AUC = 1.00, **Figure [5B](#F5){ref-type="fig"}**, V7) using CV analysis.

In conclusion, we could correctly classify PDAC, tumor-adjacent stroma, and pancreatic precursor lesions while classifier genes were not significantly altered in pancreatitis or cancers of distinct origin in FF and FFPE tissues.

Validation of Classifier Genes on Protein and Transcript Level in Patient-Derived Material
------------------------------------------------------------------------------------------

To confirm the gene expression obtained from microarrays, we tested the 17-gene classifier by RT-qPCR technology in biopsies from 8 PDACs and one liver metastasis. mRNA was extracted from fresh-frozen cancerous (*n* = 9) and non-tumor (*n* = 2) pancreas tissues. On average, all biomarker transcripts were significantly up-regulated in tumor compared to non-tumor tissues (one-sided *t*-test: *p*-value \< 0.005; **Figure [5C](#F5){ref-type="fig"}**). When looking at every patient/sample not all of the 17 genes were found up-regulated, however, the set of all classifier genes was always significantly up-regulated in cancerous versus healthy biopsies (one-sided *t*-test: *p*-value \< 0.005; **Figure [5D](#F5){ref-type="fig"}**), corroborating the need for a multi-gene instead of a single gene biomarker for detecting PDAC in individual patients.

Next, we tested the translation of the classifier genes on protein level using tissue microarrays (TMAs) from 138 pancreatic cancers for immunohistochemical staining. **Figure [6A](#F6){ref-type="fig"}** shows a representative staining for 3 classifier genes: AHNAK2, LAMC2 (cluster 4), and trefoil factor 1 (TFF1, Cluster 3), which were chosen due to their robustness for each cluster. We omitted the analysis of POSTN, the most robust gene in cluster 2, as it has been confirmed recently by immunohistochemical staining to be increased in PDAC compared to non-tumor tissues and correlating with disease progression and poor survival ([@B28]). We observed a strong positive staining for TFF1 in the PanIN state (score 3) and a strong staining for all markers in the PDAC samples (score 3). An overview of the TMA scores shows that TFF1, LAMC2 and AHNAK2 can be detected in pancreatic cancer samples with a score \> 0 in 92, 93, and 53% of all samples, respectively, whereas at least one of the markers was detectable with a score \> 0 in 99% of the samples (**Figure [6B](#F6){ref-type="fig"}**).

![**(A)** Immunohistochemical staining for AHNAK2, TFF1 and LAMC2 in normal pancreas, PanIN and PDAC patients. **(B)** Summary of immunohistochemistry scores for AHNAK2, LAMC2, TFF1 and a combined marker of all of them from 138 patients with pancreatic cancer. **(C)** ELISA-based protein detection in the blood plasma of healthy donors (*n* = 19) and PDAC patients (*n* = 21) for exemplary selected two classifier genes (TFF1, SERPINB5).](fgene-09-00108-g006){#F6}

Based on the discriminative potential of the above proteins, we investigated the possibility of detecting secreted protein candidates also in plasma samples. We selected exemplary TFF1 and serpin family B member 5 (SERPINB5), which are both secreted, and quantified their abundance using commercially available ELISA assays in plasma samples of PDAC patients. We found significantly elevated levels of these proteins (**Figure [6C](#F6){ref-type="fig"}**) in PDAC blood plasma samples (*n* = 21) compared to healthy donors (*n* = 19), although some healthy donors displayed elevated levels of both proteins.

Taken into account the to date small sample sizes, we demonstrated the possibility of a promising work-flow (**Figure [1](#F1){ref-type="fig"}**) for the establishment of a transcriptome and potential proteome biomarker based on tissue and blood plasma samples from PDAC patients. A challenge for further studies would be the applicability of biomarker genes as early detection markers, in particular reaching sufficient number of patients with pancreatic precursor lesions or non-invasive stage PDAC, which again is hindered by the late diagnosis.

Discussion
==========

The development of robust diagnostic, prognostic and predictive biomarkers for the clinical management of pancreatic adenocarcinoma has been a longstanding objective ([@B5]). We present here a robust gene expression classifier derived through integration of gene expression data from several independent studies. Data integration was achieved via the development of a novel meta-analysis using cross-validation on the level of individual patient cohorts that identified 81 genes for PDAC classification. Our workflow clearly demonstrated the need for a combination of several genes to best stratify PDAC cancer tissue, probably due to the large transcriptional heterogeneity among PDAC patients.

Consensus clustering identified four clusters among the 81 genes that were functionally associated to gene labels assigned by [@B33] exocrine/endocrine pancreas, classical and basal-like tumor and particularly activated stroma. The latter is in line with the fact that PDAC is heavily interspersed with stromal tissue ([@B14]). Additionally, PDAC samples if not microdissected, contain stromal compartments, which are included in the transcriptome analysis and therefore add to the PDAC signature. The PDAC samples used in our data (M1) contained 15--80% of tumor cells, explaining the importance of cluster 2. The exocrine/endocrine pancreas related genes (cluster 1) were all down-regulated in tumor tissues, indicating the functional decline in tumor-associated pancreas tissue. Furthermore, cluster 1 did not correlate with survival and thus turns out to be unusable to monitor the disease. Contrary to this, high and intermediate expression of genes related to stroma (cluster 2), classical (cluster 3) and basal-like (cluster 4) tumor correlated significantly with bad prognosis, making them not only diagnostic, but also prognostic biomarkers. Interestingly, patients with low expression of genes in clusters 2--4 show a highly improved 5-year survival rate (\>79%) compared to the expected rate of 5--7% ([@B42]), indicating a possibly curable stage of PDAC. This makes these genes not only a diagnostic, but also a prognostic biomarker. However, further research is needed to evaluate, at which expression level the chance of treatment response is promising.

Considering only genes within clusters with a prognostic signature on survival and those being robustly detected within the meta-analysis resulted in a manageable subset of 17 genes. We found multiple genes within the reduced 17-gene classifier that point to a dysregulation of the extracellular matrix (ECM) function in PDAC. The integrin receptors ITGA2 and ITGB6 transduce cell-cell and cell-ECM signaling, whereas POSTN, COL10A1, LAMC2, SERPINB5 and CEACAM5 bind to the integrin receptors and promote cell survival, proliferation, cell adhesion, and migration ([@B29]), processes which are also important in tumorigenesis.

Further genes are TFF1, known to induce metastasis and to regulate cancer-stroma interactions ([@B1]) and S100P, which is associated with cell proliferation and survival, and is expressed in about 50% of pancreatic lesions ([@B24]). TMPRSS4 and AHNAK2 promote epithelial to mesenchymal transition ([@B41]; [@B10]), while GABRP has been linked to PDAC progression and development ([@B44]). Lastly, KRT19 and GPRC5A can act as tumor suppressors in other cancers, but have pro-oncogenic functions in PDAC ([@B25]; [@B48]).

With respect to clinical relevance and applicability, we showed that our 17-gene classifier successfully discriminated tumor from non-tumor tissues both in FF and FFPE samples and singled out pancreatitis samples. Most importantly, it correctly classified pancreatic precursor lesions, such as PanINs and IPMNs. Identification and molecular monitoring of preinvasive precursor lesions of PDAC, is of critical importance toward increasing cure rates ([@B11]). However, material for biomarker development is sparse and often not well categorized mainly because most patients are diagnosed at advanced PDAC stages making extensive validation hard due to a lack of early detection samples. Despite our 17-gene classifier resulting from PDAC patients, it correctly classified pancreatic precursor lesions, such as PanINs and IPMNs, encouraging the transition to early stages.

Recently, [@B4] published a 5-gene classifier where 4 genes overlapped with our reported 17 genes (AHNAK2, SERPINB5, TMPRSS4 and POSTN), and epithelial cell transforming 2 (ECT2) was unique to their analysis. They selected genes that were differentially regulated in three out of four data sets and tested gene combinations ranging from 2 to 40 genes for best prediction performance in four training sets, which resulted in the 5 reported genes. In comparison, we arrived at a larger gene list (81) after unifying all suggested classifier genes from a LOOCV of six data sets. Two overlapping data sets, M3 (GSE28735) and M4 (GSE32676), in both studies allowed direct comparison of prediction performances and showed that genes obtained within our meta-analysis scored consistently better than [@B4] (AUCs of 0.95 and 0.91 vs. 0.90 and 0.88 for M3 and M4, cf. **Figure [2B](#F2){ref-type="fig"}**). Of note, we selected 45 and 40 genes within the feature selection of the meta-analysis in contrast to Bhasin's five genes, suggesting better performances for more genes.

Additionally, [@B4] used hierarchical clustering to test their 5-gene classifier on human IPMN (V6) and mouse PanIN samples (V7, **Figure [4B](#F4){ref-type="fig"}**). While their 5-gene signature separated all but one normal pancreatic duct samples, our 17-gene classifier achieved perfect separation in data set V6 (Supplementary Figure [S4A](#SM8){ref-type="supplementary-material"}). Both their 5-gene and our 17-gene classifier perfectly discriminated between normal, PanIN and PDAC cases in a genetically engineered mouse model to study PDAC progression ([@B27]) (Supplementary Figure [S4B](#SM8){ref-type="supplementary-material"}). However, prediction performance of [@B4] five genes in human PanIN samples (V5) resulted in a significantly worse performance (AUC = 0.82, Specificity = 0) compared to our 17-gene biomarker (AUC = Sensitivity = Specificity = 1). Particularly, the genes TFF1 and S100P separated IPMNs and PanINs from healthy donors, emphasizing their crucial role in detecting pancreatic precursor lesions. While the 5-gene classifier is superior to a single gene biomarker ([@B4]), the results presented here suggest the need to include further genes to increase robustly PDAC stratification. Interestingly, the 5-gene classifier contained only genes labeled related to activated stroma (POSTN) and basal-like tumor (AHNAK2, SERPINB5, TMPRSS4), and excluded classical tumor-like genes, which might explain the inferior classification performance.

In this context, we hypothesize that a widely applicable biomarker should cover the different tumor subtypes as described by the transcriptomic PDAC landscape ([@B8]; [@B33]; [@B3]). Using [@B33] class labels, the 17-classifier included representatives of the basal-like and classical like tumor subtype as well as the activated stroma. In comparison to [@B8] subtypes, we find eleven genes within the 17-gene classifier (AHNAK2, CEACAM5, CTSE, GABRP, GPRC5A, ITGA2, ITGB6, LAMC2, S100P, SLC6A14, TFF1) associated to the classical and one (POSTN) to the quasimesenchymal subtype according to their NMF scores. The exocrine-like subtype corresponded to our cluster 1 (exocrine/endocrine), including eleven representatives such as, PNLIP, PNLIPRP2, and CEL. Bailey et al. identified four different subtypes, squamous, ADEX, pancreatic progenitor, and immunogenic. There were no NMF scores of genes from clustering available, but AHNAK2, POSTN, and LAMC2 were significantly up-regulated (adj.*p*.val \< 0.05) in the squamous subtype, and TFF1 and CTSE in the progenitor subtype with respect to the other subtypes, making these genes good subtype representatives. The ADEX subtype was exclusively associated to cluster 1 (exocrine/endocrine) with 26 genes being significantly up-regulated. Interestingly, we did not find any genes significantly up-regulated in the immunogenic subtype. This can be explained by the fact that the immunogenic subtype is mostly represented by immunoglobulin genes, however, they were not included in the probe sets of the investigated microarray chips. Nevertheless, the immunogenic subtype has characteristics similar to the progenitor subtype and is part of Collisson's classical subtype, which were covered by the 17-gene classifier. Therefore, we capture the entire pancreatic cancer spectrum, with the exception of the exocrine-like ([@B8]), the ADEX ([@B3]) and the exocrine/endocrine subtype ([@B33]). Representatives of these subtypes were identified in our meta-analysis approach (cluster 1) but neglected in the 17-gene classifier because the genes showed no survival association and were down-regulated in tumor compared to normal pancreas tissue.

Despite the limited number of patients, the classifier yielded significant up-regulation in gene expression of PDAC patients versus healthy individuals, using microarray and RT-qPCR technologies and was clearly present on the protein level by TMA. Using a "liquid biopsy" approach on two exemplary chosen proteins (TFF1, SERPINB5), we found significantly elevated levels in PDAC patient blood samples compared to healthy donors, which might open up new avenues for clinical applicability and robust, minimal-invasive detection of PDAC. For this, however, larger cohort sizes, specificity compared to other cancer types and testing of further classifier-derived proteins will be needed for successful clinical translation.

Taken together, we established a novel meta-analysis pipeline for robust biomarker identification for PDAC versus non-tumor tissues, which can also be applied to different two-group experiments. Subsequent analysis revealed the diagnostic and prognostic influence of the 17-gene signature in PDAC, including pancreatic precursor lesions with application in patient tissues and liquid biopsies presenting a work-flow with potential impact in clinical transition.

Materials and Methods {#s1}
=====================

RNA Isolation and Quantitative Real Time PCR (qRT-PCR)
------------------------------------------------------

Total RNA was isolated from FF and FFPE tissue samples according to the manufacturer's protocol and as described by [@B35]. For FF tissues the Universal RNA Purification Kit from Roboklon (Germany) and for FFPE tissues the RNeasy FFPE Kit from Qiagen were used. qRT-PCR was performed as described elsewhere ([@B35]) and relative gene expression levels were calculated with the 2^-ΔΔC~T~^ method, using HPRT1 and 18S ribosomal RNA as reference genes (primers in Supplementary Table [S3](#SM3){ref-type="supplementary-material"}). Log2-fold changes were calculated compared to healthy tissue and tested for significant elevation by one-sided *t*-tests compared to log2-fold change = 0.

Microarray Preprocessing
------------------------

Total RNA was isolated, labeled and hybridized using the Whole-Genome protocol from DASL HT Assay (Illumina, San Diego, CA, United States) and Ovation^®^ FFPE WTA-Systems (NuGEN, San Carlos, CA, United States) to an Illumina humanRef-12 beadarray (Illumina, San Diego, CA, United States) according to the manufacturer's protocol. Raw bead count data was analyzed using the R/Bioconductor package beadarray ([@B13]) followed by quantile normalization and log2 transformation. Data is accessible on Gene Expression Omnibus (GEO) as GSE101448 and GSE101462. Public microarray data from GEO were downloaded in pre-processed form, i.e., normalized, log2 transformed and filtered on probe level, according to the original reference (see **Table [1](#T1){ref-type="table"}**). Since E-MEXP-1121 is a follow-up study of E-MEXP-950, we combined the two data sets from ArrayExpress. HGU133a and HGU133b chips from both studies were normalized by robust multiarray averaging (RMA) and subsequently combined, neglecting the lower inter-quartile range (IQR) if probes were present on both chips. For all data sets platform probe IDs were matched to unique EntrezIDs. In the case of multiple probes matched the same EntrezID, we chose the probe with the largest IQR.

Gene Set Enrichment Analysis
----------------------------

Enrichment of signaling pathways were performed as implemented in the R/Bioconductor package GAGE ([@B30]) with ConsensusPathDB pathways ([@B26]). Pathways were considered significant with an adjusted *p*-value \< 0.01 (Benjamini-Hochberg) and were connected by an edge if they share 30% of their genes (Supplementary Figure [S1](#SM5){ref-type="supplementary-material"}).

Single Set Biomarker Identification for M1
------------------------------------------

The data set (M1) consisting of tumor and non-tumor samples was iteratively split into testing and training samples in a 10-fold cross-validation (CV). For each testing set, we selected the features in an inner CV of the training samples to reduce the bias of overfitting. First, we obtained absolute log~2~FC differences between tumor and non-tumor tissues ([@B40]) and ranked them accordingly. Secondly, we optimized the number of genes that were selected. This is done by calculating the prediction performance when *n ∈*{1,2, ..., 10} genes were selected by applying an inner CV on the training samples. Thirdly, the top *n* genes were selected from the gene ranking, where *n* corresponds to the best prediction performance of the inner CV. These genes were then selected to train a support vector machine (SVM) on the training samples. Finally, the SVM model was used to predict tumor and non-tumor samples in the independent testing set. For all testing sets no more than two genes (SYNC and CTRB2) were sufficient for perfect prediction.

Meta-Analysis Biomarker Identification for M1--M6
-------------------------------------------------

To construct a robust gene signature discriminating between tumor and non-tumor tissues across data sets we applied a leave-one-out-cross-validation (LOOCV) approach on the independent PDAC cohorts (**Figure [3](#F3){ref-type="fig"}**). For every cross-validation run, one data set was held out for testing while the others (N-1) were used for feature selection.

### Combine Gene Rankings

First, genes were ranked within each cohort (N-1) according to their absolute differential log~2~FC between tumor and non-tumor tissue ([@B40]). Let *R~ig~* be the rank of gene g in data set i. To adjust for different total number of features, we normalized gene ranks according to the maximum rank of the data set $normR_{ig} = \frac{R_{ig} - 1}{\max(R_{i}) - 1}$. The normalized ranks were then combined by calculating their mean across data sets $aveR_{g} = \frac{1}{N - 1}{\sum_{i = 1}^{N - 1}n}ormR_{ig}$ to obtain an overall gene ranking.

### Optimize the Number of Genes to Be Selected

Secondly, to reduce the bias of overfitting, we used an inner LOOCV on training data sets to optimize the number of genes that were selected from the combined gene ranking. Therefore, we chose *n ∈*{5,10, ..., 50} with the best prediction performance in an inner LOOCV across all training data sets (N-1). Then the top *n* genes were selected from the combined gene ranking and used to evaluate the prediction performance of the selected genes.

### Evaluate Performance of Selected Genes

For a given set of genes we evaluated the prediction performance for the testing data set (in both outer and inner LOOCV) by using a SVM with a Gaussian kernel in a balanced 10-fold CV on tissue samples. SVM parameters (C, γ) were optimized using a grid search in an inner CV ([@B31]). The area under the curve (AUC) of the receiver-operating characteristic (ROC) served as performance evaluation metric ([@B43]).

For every testing data set, between 35 and 50 genes were chosen in the feature selection, which combined to a total of 81 unique classifier genes.

Consensus Clustering
--------------------

We used the ConsensusClusterPlus package ([@B45]) with Ward's clustering and Spearman correlation distance metric to cluster genes in M1--M6. The optimal number of clusters *k = 4* was obtained by investigating the empirical cumulative distribution function (CDF) and its relative change as proposed by [@B45] (Supplementary Figures [S5A,B](#SM9){ref-type="supplementary-material"}).

Survival Analysis
-----------------

RMSE normalized gene expression data of 178 PDAC samples and their associated survival information were downloaded from TCGA. Based on the consensus clusters, we applied Ward's hierarchical clustering on expression data using Euclidean distances to divide patients into low, intermediate and high expression groups (Supplementary Figure [S3](#SM7){ref-type="supplementary-material"}). Survival rates were analyzed using Kaplan--Meier plots and log-rank tests.

Validation Analysis
-------------------

Prediction performances were estimated by 10-fold CV with SVM on validation data sets with classifier genes as features as described "Evaluate Performance of Selected Genes" in "Materials and Methods." To compare PDAC to other cancers, we obtained RMSE normalized gene expression data from TCGA for bladder, breast, colon, liver, and thyroid cancer.

An overview about the statistical methods used is given in Supplementary Table [S4](#SM4){ref-type="supplementary-material"} and the meta-analysis algorithm has been uploaded to: <https://github.com/hklett/meta-analysis.git>.

Immunohistochemistry
--------------------

All patients were treated at the Clinic for General and Visceral Surgery and histopathological work-up was performed at the Institute of Surgical Pathology, both University Medical Center Freiburg, Germany. All tumor samples were reviewed by experienced pathologists. In total, 138 patients were included in tissue microarray (TMA) analysis. Before core biopsy was withdrawn from the donator and inserted into the acceptor paraffin block, tumor tissue was outlined at the corresponding hematoxylin-eosin slide. Each TMA comprised up to 24 patients. All patients were represented by two core biopsies with a core diameter of 2 mm. Hereby, each core biopsy was allocated at a separate TMA-block. Serial 2 μm thick tissue slices were prepared for Estrogen Inducible Protein ps2 (TFF1; ab92377, Abcam plc, Cambridge, United Kingdom), anti-LAMC2 (HPA024638, Sigma-Aldrich, Munich Germany) and anti-AHNAK2 (HPA002940, Sigma Aldrich, Munich, Germany). Slides were dried at 56°C overnight to improve adherence to the objective plate and then deparaffinized in xylene and decreasing ethanol concentrations. For TFF1 and LAMC2, heat mediated epitope retrieval was performed for 20 min at pH 6.1 and 95°C. For AHNAK2 epitope retrieval was not necessary. For all antibodies immunohistochemistry (IHC) was performed using the Autostainer plus and stained afterward with Dako Real^®^ Detection System (Dako K5001) according to the manufacturer's guidelines. Negative control was performed via omission of primary antibody. Two pathologists blinded for patient data, reviewed Anti-TFF1, Anti-LAMC2 and Anti-AHNAK2 according to the following protocol. Using 200-fold magnification, antibody expression was analyzed in each core biopsy using a semi-quantitative expression analyses for antibody intensity (score 0 = none, 1 = low, 2 = intermediate, 3 = strong) and percentage of positive (range 0--100%, intervals of 5%) tumor cells.

Enzyme-Linked Immunosorbent Assays
----------------------------------

Enzyme-linked immunosorbent assays (ELISA) of TFF1 and SERPINB5 were performed following the manufacturer's instructions (SEB049Hu, Cloud-Clone Corp. Houston, TX, United States; LS-F13455, LifeSpan BioSciences Inc., Seattle, WA, United States). The antibodies for detection of TFF1 and SERPINB5 were provided with the respective kits. The plasma samples were diluted by a factor of four. Standard or blood plasma samples (100 μl) were pipetted on a provided plate in duplicates and incubated at 37°C for 1 h. TFF1 and SERPINB5 proteins were detected using the provided detection reagents and the plate was read at 450 nm using a TECAN Infinite M200PRO plate reader.
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